These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 3382171

  • 21. Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics.
    Taal W, van der Rijt CC, Dinjens WN, Sillevis Smitt PA, Wertenbroek AA, Bromberg JE, van Heuvel I, Kros JM, van den Bent MJ.
    J Neurooncol; 2015 Jan; 121(2):365-72. PubMed ID: 25344884
    [Abstract] [Full Text] [Related]

  • 22. Primary intracranial gliomas: clinical studies and treatment regimens of the Brain Tumor Research Center, University of California, San Francisco, 1977-1979.
    Levin VA, Wilson CB, Vestnys PS.
    Cancer Treat Rep; 1981 Jan; 65 Suppl 2():83-8. PubMed ID: 7049363
    [No Abstract] [Full Text] [Related]

  • 23. [Clinical significance of mustoforan in management of malignant glioma].
    Kobiakov GL.
    Vopr Onkol; 2007 Jan; 53(6):724-9. PubMed ID: 18416147
    [No Abstract] [Full Text] [Related]

  • 24. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group.
    van den Bent MJ, Kros JM, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HG, Taphoorn MJ, Zonnenberg BA, Tijssen CC, Twijnstra A, Punt CJ, Boogerd W.
    Neurology; 1998 Oct; 51(4):1140-5. PubMed ID: 9781544
    [Abstract] [Full Text] [Related]

  • 25. An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.
    Halperin EC, Gaspar L, Imperato J, Salter M, Herndon J, Dowling S.
    Am J Clin Oncol; 1993 Aug; 16(4):277-83. PubMed ID: 8392285
    [Abstract] [Full Text] [Related]

  • 26. Chemotherapy for malignant gliomas of the brain: a review of ten-years experience.
    Paoletti P, Butti G, Knerich R, Gaetani P, Assietti R.
    Acta Neurochir (Wien); 1990 Aug; 103(1-2):35-46. PubMed ID: 2360465
    [Abstract] [Full Text] [Related]

  • 27. Chemotherapy for oligodendroglioma. Progress report.
    Cairncross JG, Macdonald DR.
    Arch Neurol; 1991 Feb; 48(2):225-7. PubMed ID: 1993014
    [No Abstract] [Full Text] [Related]

  • 28. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial.
    Taphoorn MJ, van den Bent MJ, Mauer ME, Coens C, Delattre JY, Brandes AA, Sillevis Smitt PA, Bernsen HJ, Frénay M, Tijssen CC, Lacombe D, Allgeier A, Bottomley A, European Organisation for Research and Treatment of Cancer.
    J Clin Oncol; 2007 Dec 20; 25(36):5723-30. PubMed ID: 18089866
    [Abstract] [Full Text] [Related]

  • 29. Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas.
    Chamberlain MC, Kormanik PA.
    J Clin Oncol; 1997 Dec 20; 15(12):3427-32. PubMed ID: 9396393
    [Abstract] [Full Text] [Related]

  • 30. Nitrosourea chemotherapy for primary malignant gliomas.
    Levin VA, Wilson CB.
    Cancer Treat Rep; 1976 Jun 20; 60(6):719-24. PubMed ID: 954010
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. A pilot study of dose-intensified procarbazine, CCNU, vincristine for poor prognosis brain tumors utilizing fibronectin-assisted, retroviral-mediated modification of CD34+ peripheral blood cells with O6-methylguanine DNA methyltransferase.
    Cornetta K, Croop J, Dropcho E, Abonour R, Kieran MW, Kreissman S, Reeves L, Erickson LC, Williams DA.
    Cancer Gene Ther; 2006 Sep 20; 13(9):886-95. PubMed ID: 16645619
    [Abstract] [Full Text] [Related]

  • 33. Low-grade oligodendroglioma responds to chemotherapy.
    Mason WP, Krol GS, DeAngelis LM.
    Neurology; 1996 Jan 20; 46(1):203-7. PubMed ID: 8559376
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Single-agent chemotherapy of brain tumors. A five-year review.
    Wilson CB, Gutin P, Boldrey EB, Drafts D, Levin VA, Enot KJ.
    Arch Neurol; 1976 Nov 20; 33(11):739-44. PubMed ID: 185991
    [Abstract] [Full Text] [Related]

  • 37. Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma.
    Tang BN, Sadeghi N, Branle F, De Witte O, Wikler D, Goldman S.
    J Neurooncol; 2005 Jan 20; 71(2):161-8. PubMed ID: 15690133
    [Abstract] [Full Text] [Related]

  • 38. A review of studies of the EORTC brain tumor group.
    Hildebrand J.
    Cancer Treat Rep; 1981 Jan 20; 65 Suppl 2():89-94. PubMed ID: 7049364
    [Abstract] [Full Text] [Related]

  • 39. Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma.
    Paleologos NA, Macdonald DR, Vick NA, Cairncross JG.
    Neurology; 1999 Sep 22; 53(5):1141-3. PubMed ID: 10496285
    [Abstract] [Full Text] [Related]

  • 40. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up.
    Abrey LE, Childs BH, Paleologos N, Kaminer L, Rosenfeld S, Salzman D, Finlay JL, Gardner S, Peterson K, Hu W, Swinnen L, Bayer R, Forsyth P, Stewart D, Smith AM, Macdonald DR, Weaver S, Ramsay DA, Nimer SD, DeAngelis LM, Cairncross JG.
    Neuro Oncol; 2006 Apr 22; 8(2):183-8. PubMed ID: 16524945
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.